Information for the public

NICE has not recommended the PROGENSA PCA3 assay and the Prostate Health Index for use in people having investigations for suspected prostate cancer, who have had a negative or inconclusive transrectal ultrasound prostate biopsy. The PCA3 assay is diagnostic test that detects the level of prostate cancer gene 3 (PCA3) in urine, and the PHI is a diagnostic test that detects the level of differing forms of prostate-specific antigen (PSA) in blood.

ISBN: 978-1-4731-1180-6


This page was last updated: 07 May 2015